ATE156711T1 - Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) - Google Patents

Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Info

Publication number
ATE156711T1
ATE156711T1 AT92902288T AT92902288T ATE156711T1 AT E156711 T1 ATE156711 T1 AT E156711T1 AT 92902288 T AT92902288 T AT 92902288T AT 92902288 T AT92902288 T AT 92902288T AT E156711 T1 ATE156711 T1 AT E156711T1
Authority
AT
Austria
Prior art keywords
insulin
treatment
monoclonal antibodies
iddm
diabetes mellitus
Prior art date
Application number
AT92902288T
Other languages
English (en)
Inventor
Anne Cooke
Herman Waldmann
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE156711T1 publication Critical patent/ATE156711T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92902288T 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) ATE156711T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919100741A GB9100741D0 (en) 1991-01-14 1991-01-14 Treatment of disease

Publications (1)

Publication Number Publication Date
ATE156711T1 true ATE156711T1 (de) 1997-08-15

Family

ID=10688399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92902288T ATE156711T1 (de) 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Country Status (10)

Country Link
US (1) US5670150A (de)
EP (1) EP0567490B1 (de)
JP (1) JP3168005B2 (de)
AT (1) ATE156711T1 (de)
AU (1) AU668081B2 (de)
CA (1) CA2100462C (de)
DE (1) DE69221605T2 (de)
ES (1) ES2106169T3 (de)
GB (1) GB9100741D0 (de)
WO (1) WO1992011869A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218062A1 (en) * 2006-03-16 2007-09-20 Genentech, Inc. Methods of treating lupus using CD4 antibodies
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
KR102721494B1 (ko) * 2018-04-17 2024-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0380018B1 (de) * 1989-01-23 1995-07-19 Abbott Laboratories Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies

Also Published As

Publication number Publication date
DE69221605D1 (de) 1997-09-18
EP0567490A1 (de) 1993-11-03
WO1992011869A1 (en) 1992-07-23
AU1164792A (en) 1992-08-17
US5670150A (en) 1997-09-23
JPH06504283A (ja) 1994-05-19
EP0567490B1 (de) 1997-08-13
JP3168005B2 (ja) 2001-05-21
ES2106169T3 (es) 1997-11-01
CA2100462C (en) 2003-06-17
CA2100462A1 (en) 1992-07-15
DE69221605T2 (de) 1998-02-12
AU668081B2 (en) 1996-04-26
GB9100741D0 (en) 1991-02-27

Similar Documents

Publication Publication Date Title
ES2109228T3 (es) Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.
DK0528931T3 (da) Humaniserede kimæriske anti-ICAM-1 antistoffer, fremgangsmåder til fremstilling deraf og anvendelse deraf
PT724456E (pt) Anticorpos contra cd4
DK0617575T3 (da) Indretning til dyrkning af planter
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
FI98510B (fi) Vateriitti ja menetelmä sen valmistamiseksi
DE69019345D1 (de) Zusammensetzung zur behandlung von samen.
FI893428A7 (fi) TNF-a:n in vitro ja in vivo toksisten ominaisuuksien eliminointi monoklonaalisilla vasta-aineilla ja niistä johdetuilla fragmenteilla
DE3162128D1 (en) Biologically active compounds, their obtention from human casein and compositions containing them
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
DE69012304D1 (de) Einrichtung zur Augenbehandlung.
EP0160486A3 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties